J&J li­cens­es LegoChem's Trop2 ADC for $100M up­front

John­son and John­son’s sub­sidiary Janssen is li­cens­ing a Trop2 di­rect­ed an­ti­body-drug con­ju­gate from South Ko­rea’s LegoChem Bio­sciences in a deal that could be worth as much as $1.7 bil­lion.

Along with a $100 mil­lion up­front cash pay­ment, LegoChem will get an op­tion ex­er­cise pay­ment of $200 mil­lion and po­ten­tial fu­ture mile­stones and tiered roy­al­ties on net sales. Both com­pa­nies will work on an on­go­ing Phase I/II tri­al of the drug can­di­date, LCB84, while J&J will work on clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion af­ter the op­tion ex­er­cise.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER